{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T02:58:18Z","timestamp":1770346698238,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T00:00:00Z","timestamp":1498003200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010445","name":"European Society of Veterinary Ophthalmology","doi-asserted-by":"crossref","award":["Research Grant (ESVO-2015)"],"award-info":[{"award-number":["Research Grant (ESVO-2015)"]}],"id":[{"id":"10.13039\/501100010445","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/CVT\/00276\/2013"],"award-info":[{"award-number":["UID\/CVT\/00276\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2013"],"award-info":[{"award-number":["UID\/DTP\/04138\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s13346-017-0399-y","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T17:43:31Z","timestamp":1498067011000},"page":"625-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9135-2743","authenticated-orcid":false,"given":"Ana Paula","family":"Resende","sequence":"first","affiliation":[]},{"given":"Beatriz","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Berta S\u00e3o","family":"Braz","sequence":"additional","affiliation":[]},{"given":"Telmo","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"L\u00eddia","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Esmeralda","family":"Delgado","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,6,21]]},"reference":[{"key":"399_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.joco.2016.01.008","volume":"28","author":"KV Aghdam","year":"2016","unstructured":"Aghdam KV, et al. Erythropoietin in ophthalmology: a literature review. J Curr Ophthalmol. 2016;28:5\u201311.","journal-title":"J Curr Ophthalmol"},{"key":"399_CR2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1258\/ebm.2010.010137","volume":"235","author":"JW Fisher","year":"2010","unstructured":"Fisher JW. Landmark advances in the development of erythropoietin. Exp Biol Med. 2010;235:1398\u2013411.","journal-title":"Exp Biol Med"},{"key":"399_CR3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000369885","volume":"53","author":"W Luo","year":"2015","unstructured":"Luo W, et al. The protective effect of erythropoietin on the retina. Ophthalmic Res. 2015;53:74\u201381.","journal-title":"Ophthalmic Res"},{"issue":"5","key":"399_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dnp.2007.20.5.1120219","volume":"20","author":"G Grasso","year":"2007","unstructured":"Grasso G, et al. The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect. 2007;20(5):315\u201320.","journal-title":"Drug News Perspect"},{"issue":"5","key":"399_CR5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.neuro.2005.01.016","volume":"26","author":"S Bartesaghi","year":"2005","unstructured":"Bartesaghi S, et al. Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology. 2005;26(5):923\u20138.","journal-title":"Neurotoxicology"},{"issue":"5","key":"399_CR6","first-page":"523","volume":"22","author":"WS Bond","year":"2014","unstructured":"Bond WS, Rex TS. Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front Immunol. 2014;22(5):523.","journal-title":"Front Immunol"},{"issue":"3","key":"399_CR7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1167\/iovs.06-0757","volume":"48","author":"L Zhong","year":"2007","unstructured":"Zhong L, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA\/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48(3):1212\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"399_CR8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/02713680500320729","volume":"30","author":"JC Tsai","year":"2005","unstructured":"Tsai JC, et al. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res. 2005;30:1025\u201331.","journal-title":"Curr Eye Res"},{"issue":"5","key":"399_CR9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/jop.2008.0021","volume":"24","author":"Y-S Zhong","year":"2008","unstructured":"Zhong Y-S, et al. Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther. 2008;24(5):453\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"399_CR10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2007.01.017","volume":"205","author":"CE King","year":"2007","unstructured":"King CE, et al. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol. 2007;205(1):48\u201355.","journal-title":"Exp Neurol"},{"key":"399_CR11","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/bjo.2008.156794","volume":"93","author":"WA Lagreze","year":"2009","unstructured":"Lagreze WA, et al. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009;93:1667\u201371.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"399_CR12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00417-007-0671-9","volume":"245","author":"Y Zhong","year":"2007","unstructured":"Zhong Y, et al. Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1859\u201367.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3\u20134","key":"399_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","volume":"13","author":"SK Sahoo","year":"2008","unstructured":"Sahoo SK, et al. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3\u20134):144\u201351.","journal-title":"Drug Discov Today"},{"issue":"9","key":"399_CR14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/17425255.2013.796928","volume":"9","author":"J Jordan","year":"2013","unstructured":"Jordan J, Ruiz-Moreno JM. Advances in the understanding of retinal drug disposition and the role of blood\u2013ocular barrier transporters. Expert Opin Drug Metab Toxicol. 2013;9(9):1181\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"399_CR15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00417-013-2367-7","volume":"251","author":"AP Resende","year":"2013","unstructured":"Resende AP, et al. Alternative route for erythropoietin ocular administration. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):2051\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"399_CR16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000444327","volume":"56","author":"AP Resende","year":"2015","unstructured":"Resende AP, et al. Ocular erythropoietin penetration after subconjunctival administration in glaucomatous rats. Ophthalmic Res. 2015;56(2):104\u201310.","journal-title":"Ophthalmic Res"},{"issue":"7","key":"399_CR17","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/jps.24465","volume":"104","author":"S Pescina","year":"2015","unstructured":"Pescina S, et al. Permeation of proteins, oligonucleotide and dextrans across ocular tissues: experimental studies and a literature update. J Pharm Sci. 2015;104(7):2190\u2013202.","journal-title":"J Pharm Sci"},{"issue":"190","key":"399_CR18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","volume":"28","author":"YC Kim","year":"2014","unstructured":"Kim YC, et al. Ocular delivery of macromolecules. J Control Release. 2014;28(190):172\u201381.","journal-title":"J Control Release"},{"issue":"3","key":"399_CR19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/S1517-86922003000300006","volume":"9","author":"R Bento","year":"2003","unstructured":"Bento R, et al. Recombinant human erythropoietin in sports: a review. Rev Bras Med Esporte. 2003;9(3):181\u201390.","journal-title":"Rev Bras Med Esporte"},{"key":"399_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2004.12.007","volume":"60","author":"K Hosoya","year":"2005","unstructured":"Hosoya K, Lee VHL, Kim KJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm. 2005;60:227\u201340.","journal-title":"Eur J Pharm Biopharm"},{"key":"399_CR21","unstructured":"Maggs D et al. Slatter\u2019s fundamentals of veterinary ophthalmology. 4th ed. Saunders; 2008."},{"key":"399_CR22","first-page":"39","volume-title":"Ophthalmic anatomy","author":"D Samuelson","year":"2013","unstructured":"Samuelson D. Ophthalmic anatomy. In: Gelatt K et al. Wiley-Blackwell; 2013. p. 39\u2013170."},{"key":"399_CR23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jps.23387","volume":"102","author":"H Wen","year":"2013","unstructured":"Wen H, et al. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. J Pharm Sci. 2013;102:892\u2013903.","journal-title":"J Pharm Sci"},{"key":"399_CR24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.2042-7158.2010.01153.x","volume":"62","author":"S Pescina","year":"2010","unstructured":"Pescina S, et al. In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application. J Pharm Pharmacol. 2010;62:1189\u201394.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"399_CR25","first-page":"1181","volume":"41","author":"J Ambati","year":"2000","unstructured":"Ambati J, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41(5):1181\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"399_CR26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s13346-015-0275-6","volume":"6","author":"P Agarwal","year":"2016","unstructured":"Agarwal P, Rupenthal ID. In vitro and ex vivo corneal penetration and absorption models. Drug Deliv Transl Res. 2016;6(6):634\u201347.","journal-title":"Drug Deliv Transl Res"},{"key":"399_CR27","unstructured":"Development and validation of in vitro release testing methods for semisolid formulation. Particle Sciences, Inc. Technical Brief. 2009; 10."},{"key":"399_CR28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/B978-1-4377-1926-0.10002-5","volume-title":"Clinical anatomy and physiology of the visual system","author":"LA Remington","year":"2012","unstructured":"Remington LA. Cornea and sclera. In: Remington LA, editor. Clinical anatomy and physiology of the visual system. 3rd ed. Saint Louis: Butterworth-Heinemann; 2012. p. 10\u201339.","edition":"3rd"},{"key":"399_CR29","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50:4807\u201313.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"399_CR30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/jop.2007.0061","volume":"24","author":"AM Demetriades","year":"2008","unstructured":"Demetriades AM, et al. Trans-scleral delivery of antiangiogenic proteins. J Ocul Pharmacol Ther. 2008;24:70\u20139.","journal-title":"J Ocul Pharmacol Ther"},{"key":"399_CR31","first-page":"2270","volume-title":"Retina","author":"VHL Lee","year":"2001","unstructured":"Lee VHL, Hosoya K. Drug delivery to the posterior segment. In: Ryan SJ, editor. Retina. 3rd ed. St Louis, MO: Mosby; 2001. p. 2270\u201385.","edition":"3rd"},{"issue":"3","key":"399_CR32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/1389200033489488","volume":"4","author":"SB Koevary","year":"2003","unstructured":"Koevary SB. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab. 2003;4(3):213\u201322.","journal-title":"Curr Drug Metab"},{"key":"399_CR33","unstructured":"Zhu A, Martosella J & Duong PT. Peptide mapping of glycoprotein erythropoietin by HILIC LC\/MS and RP-LC\/MS. Agilent Technologies, Inc., USA May 10, 2013."},{"key":"399_CR34","doi-asserted-by":"crossref","unstructured":"Shirley Ding SL et al. Revisiting the role of erythropoietin for treatment of ocular disorders. Eye (London, England). 2016; 30(10):1293\u20131309.","DOI":"10.1038\/eye.2016.94"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-017-0399-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-017-0399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-017-0399-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:48:34Z","timestamp":1589762914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-017-0399-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,21]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s13346-017-0399-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,21]]}}}